Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of 64
million people globally. Although the incidence of HF has stabilised worldwide and seems to …

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart
failure cases and has a prevalence that is expected to rise with the growing ageing …

Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognised and
diagnosed in clinical practice, a trend driven by an ageing population and a rise in …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

Heart failure (HF) is a global pandemic affecting 64 million people worldwide. HF with
preserved ejection fraction (HFpEF) has traditionally received less attention than its main …

Background Acute heart failure (AHF) is associated with a poor prognosis regardless of left
ventricular ejection fraction (LVEF). STRONG-HF showed the efficacy and safety of a …

The aim of this narrative review is to summarize contemporary evidence on the use of
circulating cardiac biomarkers of heart failure (HF) and to identify a promising biomarker …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a global health care problem,
with diagnostic difficulty, limited treatment options and high morbidity and mortality rates …

Heart failure with preserved ejection fraction (HFpEF) has a high prevalence, affecting more
than 50% of patients with heart failure. HFpEF is associated with multiple comorbidities, and …